Vivos Therapeutics, Inc. (VVOS)
| Market Cap | 7.43M |
| Revenue (ttm) | 13.80M |
| Net Income (ttm) | -13.58M |
| Shares Out | 2.73M |
| EPS (ttm) | -11.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,100 |
| Open | 2.690 |
| Previous Close | 2.660 |
| Day's Range | 2.610 - 2.740 |
| 52-Week Range | 2.400 - 48.790 |
| Beta | 7.90 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 6, 2024 |
About VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and... [Read more]
Financial Performance
In 2023, VVOS's revenue was $13.80 million, a decrease of -13.87% compared to the previous year's $16.02 million. Losses were -$13.58 million, -43.04% less than in 2022.
Financial StatementsNews
Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea ...
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos' Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos De...
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA
New Dentist Inquiries Jumped 600% and Signed Dentist Enrollment Contracts up 38% Sequentially Over Q3 CARE Oral Medical Device Unit Orders Increased 26% Following FDA Clearance LITTLETON, Colo., Jan. ...
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA Vivos unites influential women l...
Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance
Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea.
US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea
Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA).
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos With this unprec...
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expe...
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for pat...
Vivos Therapeutics Closes $4 Million Private Placement
LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for pat...
Vivos Therapeutics Announces Reverse Stock Split
1-for-25 reverse stock split to become effective as of the opening of trading tomorrow, October 27, 2023 1-for-25 reverse stock split to become effective as of the opening of trading tomorrow, October...
Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement
Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine
Randomized controlled clinical trial using Vivos' DNA Oral Appliance Therapy to study the DNA's impact on OSA versus CPAP Randomized controlled clinical trial using Vivos' DNA Oral Appliance Therapy t...
Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion
Vivos Executes Distribution Agreement with Established Dubai-based Sleep Testing Company Subject to Regulatory Approvals, Vivos Could See Revenue From This Collaboration in 2024 LITTLETON, Colo., Oct....
Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers
New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained Providers New Relationshi...
New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference
Vivos Attracts Wide Group of Experts in Dental and Medical Disciplines With a Shared Vision to Treat the Millions of Patients Suffering with Breathing-Related Sleep Disorders Vivos Attracts Wide Group...
Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update
Operating Expenses Decreased 31% Quarter Over Quarter and 25% Year to Date, Reflecting Cost Cutting Initiatives
Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call
LITTLETON, Colo., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovati...
Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call
LITTLETON, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovativ...
Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call
LITTLETON, Colo., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovati...
Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update
Revenue increased 6% Year-Over-Year; Operating Expenses Decreased 20% as Cost Cutting Initiatives Take Hold
Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call
LITTLETON, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovati...
Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos' POD® Appliance Treatment
Study Data Highlights New Vivos Treatment Option is Highly Effective in Treating Migraine Headaches, One of the World's Most Common Illnesses Study Data Highlights New Vivos Treatment Option is Highly...